Janssen-Cilag International NV, has submitted a Marketing Authorisation Application to the European Medicines Agency for paliperidone palmitate, an investigational once-monthly atypical antipsychotic intramuscular injection for the treatment of schizophrenia.

Paliperidone palmitate utilises the NanoCrystal Technology, which is a proprietary technology developed by Elan Drug Technologies through Elan Pharma International Limited and other Elan affiliates.

The paliperidone palmitate filing is based on an extensive global clinical development programme. Paliperidone palmitate was approved in the United States in July 2009. Marketing applications in other regions of the world are ongoing.

Upon approval, paliperidone palmitate will be marketed in Europe by the Janssen-Cilag companies, subsidiaries of Johnson & Johnson, the world's most comprehensive manufacturer of health-care products and related services.

The Janssen-Cilag companies are part of the Johnson & Johnson family of companies. They have a long track record in developing and marketing treatments for central nervous system disorders, pain management, oncology, infectious diseases, reproductive health and gastrointestinal disorders.

NanoCrystal Technology is a registered trademark of Elan Pharma International Limited, Ireland, a subsidiary of Elan Corporation plc.